ClinicalTrials.gov
ClinicalTrials.gov Menu

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03041324
Recruitment Status : Recruiting
First Posted : February 2, 2017
Last Update Posted : June 7, 2018
Sponsor:
Information provided by (Responsible Party):
Sangamo Therapeutics

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : February 2021
  Estimated Study Completion Date : February 2022